Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CORTONE vs CORTENEMA
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
Adrenocortical insufficiency,Inflammatory conditions (e.g., rheumatoid arthritis, allergic reactions),Autoimmune diseases,Dermatologic disorders
Adjunctive therapy for ulcerative colitis (proctitis, proctosigmoiditis, left-sided colitis) as a retention enema
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
One enema (100 mg hydrocortisone in 60 m L) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Cortisone is metabolized in the liver primarily by 11β-hydroxysteroid dehydrogenase type 1 to active cortisol; further metabolism via CYP3A4 and other reductases.
GFR 10-50 m L/min: use 75% of normal dose. GFR <10 m L/min: use 50% of normal dose.
No specific dose adjustment recommended; use with caution in severe renal impairment.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 25%. Class C: reduce dose by 50%.
No FDA black box warning for CORTONE.
CORTONE (cortisone) is a corticosteroid. In the first trimester, systemic use may be associated with a small increased risk of cleft palate (odds ratio ~1.3-1.5). In the second and third trimesters, chronic high doses may cause fetal adrenal suppression, intrauterine growth restriction, and premature birth. Risk is dose-dependent and duration-dependent.
CORTENEMA (hydrocortisone enema) is a corticosteroid. In animal studies, corticosteroids have been shown to be teratogenic. However, in humans, topical administration with minimal systemic absorption is considered low risk. There are no adequate and well-controlled studies in pregnant women. Use in first trimester: theoretical risk of cleft palate; second/third trimester: risk of fetal adrenal suppression if significant systemic absorption occurs. Because systemic absorption from rectal administration is limited, risk is likely low.
Cortone (cortisone acetate) is a glucocorticoid with significant mineralocorticoid activity; monitor for sodium retention, hypokalemia, and hypertension. Taper withdrawal to avoid adrenal crisis. Use lowest effective dose. Not for acute stress unless supplemental doses given. Contraindicated in systemic fungal infections.
CORTENEMA (hydrocortisone rectal enema) is a topically acting corticosteroid for distal ulcerative colitis. Administer at bedtime to maximize retention time. Avoid use in patients with systemic fungal infections or recent bowel anastomosis. Taper dose gradually to avoid adrenal suppression. Monitor for glucocorticoid side effects with prolonged use.
No interactions on record
No interactions on record
CORTONE and CORTENEMA are distinct pharmacological agents. CORTONE belongs to the Corticosteroid class and is primarily used for Adrenocortical insufficiencyInflammatory conditions (e.g., rheumatoid arthritis, allergic reactions)Autoimmune diseasesDermatologic disorders. CORTENEMA belongs to the Corticosteroid class and is primarily used for Adjunctive therapy for ulcerative colitis (proctitis, proctosigmoiditis, left-sided colitis) as a retention enema. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. CORTONE carries a safety status of Category C, whereas CORTENEMA safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via CYP3A4; systemic absorption occurs but limited due to topical administration; metabolites are inactive.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
~90% bound to corticosteroid-binding globulin (CBG) and albumin.
80-90% (primarily to corticosteroid-binding globulin and albumin)
0.3-0.5 L/kg; distributes into total body water.
0.5-1.4 L/kg (suggests extensive tissue distribution; not clinically adjusted for rectal use)
Oral: ~25% due to extensive first-pass metabolism; IM: 100%.
Approximately 30-50% (rectal); systemic absorption limited by first-pass hepatic metabolism and local retention
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
Oral: 0.1-2.8 mg/kg/day in 3-4 divided doses; IM/IV: 0.5-4.0 mg/kg/day every 6-12 hours.
Not recommended for pediatric use due to lack of safety and efficacy data.
Initiate at lower end of dosing range; monitor for fluid retention, hyperglycemia, and osteoporosis; use lowest effective dose.
Use with caution; monitor for fluid retention, hypertension, and hyperglycemia due to increased risk of corticosteroid side effects.
None
Systemic corticosteroid effects possible with prolonged use; adrenal suppression; increased risk of infections; masking of infection; gastrointestinal perforation; delayed wound healing; osteoporosis; growth suppression in children; ocular effects (cataracts, glaucoma).
Systemic fungal infections; known hypersensitivity to any component of the product; ileocolostomy or obstruction; extensive fistulas; acute surgical abdomen.
Avoid grapefruit and grapefruit juice (can increase cortisone levels). Limit high-sodium foods to reduce fluid retention. May require increased potassium intake (bananas, oranges) if hypokalemic. Avoid alcohol as it may increase risk of GI ulcers.
No specific food interactions. Avoid alcohol and spicy foods if they exacerbate colitis symptoms.
Cortisone transfers into breast milk in low quantities. The M/P ratio is approximately 0.3-0.5. At maternal doses ≤ 40 mg/day, infant exposure is negligible and considered compatible with breastfeeding. Higher doses may require monitoring infant for adrenal suppression.
Corticosteroids are excreted in human milk in small amounts. M/P ratio not specifically available for hydrocortisone enema. With limited systemic absorption from rectal use, concentrations in breast milk are expected to be low. However, caution is advised. No known adverse effects in nursing infants at therapeutic maternal doses.
Pregnancy increases clearance of cortisone due to increased hepatic metabolism and plasma volume expansion. Dose adjustments may be necessary, particularly for chronic therapy; typically, doses are increased by 20-50% in late pregnancy. For physiologic replacement, monitoring of cortisol levels is recommended.
No pharmacokinetic data specific to pregnancy for rectal hydrocortisone. Systemic absorption is minimal. Dose adjustments not typically required; use at lowest effective dose.
Take with food or milk to reduce stomach upset.,Do not stop suddenly; follow your doctor's tapering plan.,Report signs of infection (fever, sore throat) or unusual weight gain/swelling.,Avoid live vaccines while on this medication.,Carry a medical alert card indicating steroid use.,Monitor blood sugar if diabetic; may increase blood glucose.,Avoid grapefruit juice as it can increase drug levels.
Use the enema at bedtime to allow overnight retention.,Lie on your left side during administration and remain lying down for at least 30 minutes.,Do not use for more than 3 weeks unless directed by your doctor.,Report any signs of infection, rectal bleeding, or systemic corticosteroid effects.,Do not stop abruptly; follow tapering instructions.